{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T15:02:20Z","timestamp":1778770940053,"version":"3.51.4"},"reference-count":116,"publisher":"Elsevier","isbn-type":[{"value":"9780443294440","type":"print"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/bs.acr.2024.06.004","type":"book-chapter","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T21:28:46Z","timestamp":1719955726000},"page":"145-171","source":"Crossref","is-referenced-by-count":5,"title":["Melanoma redox biology and the emergence of drug resistance"],"prefix":"10.1016","author":[{"given":"Therese","family":"Featherston","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Paumann-Page","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark B.","family":"Hampton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/bs.acr.2024.06.004_bib1","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s12672-021-00439-0","article-title":"The gold complex auranofin: new perspectives for cancer therapy","volume":"12","author":"Abdalbari","year":"2021","journal-title":"Discover Oncology"},{"issue":"3","key":"10.1016\/bs.acr.2024.06.004_bib2","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.molmed.2014.12.007","article-title":"Molecular drivers of cellular metabolic reprogramming in melanoma","volume":"21","author":"Abildgaard","year":"2015","journal-title":"Trends in Molecular Medicine"},{"issue":"7","key":"10.1016\/bs.acr.2024.06.004_bib3","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic classification of cutaneous melanoma","volume":"161","author":"Akbani","year":"2015","journal-title":"Cell"},{"issue":"12","key":"10.1016\/bs.acr.2024.06.004_bib4","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1002\/mc.22708","article-title":"NADPH oxidase 5 (NOX5)-induced reactive oxygen signaling modulates normoxic HIF-1\u03b1 and p27(Kip1) expression in malignant melanoma and other human tumors","volume":"56","author":"Antony","year":"2017","journal-title":"Mol Carcinog"},{"issue":"4","key":"10.1016\/bs.acr.2024.06.004_bib5","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbamcr.2008.02.003","article-title":"Thioredoxins and glutaredoxins as facilitators of protein folding","volume":"1783","author":"Berndt","year":"2008","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Cell Research"},{"issue":"9","key":"10.1016\/bs.acr.2024.06.004_bib6","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/nchembio.1038","article-title":"Peroxidasin forms sulfilimine chemical bonds using hypohalous acids in tissue genesis","volume":"8","author":"Bhave","year":"2012","journal-title":"Nature Chemical Biology"},{"issue":"20","key":"10.1016\/bs.acr.2024.06.004_bib7","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1158\/0008-5472.CAN-19-3588","article-title":"An integrative gene expression and mathematical flux balance analysis identifies targetable redox vulnerabilities in melanoma cells","volume":"80","author":"Bishal Paudel","year":"2020","journal-title":"Cancer Research"},{"issue":"11","key":"10.1016\/bs.acr.2024.06.004_bib8","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/nrd3847","article-title":"Vemurafenib: the first drug approved for BRAF-mutant cancer","volume":"11","author":"Bollag","year":"2012","journal-title":"Nature reviews Drug discovery"},{"key":"10.1016\/bs.acr.2024.06.004_bib9","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.freeradbiomed.2016.04.001","article-title":"Mitochondrial generation of superoxide and hydrogen peroxide as the source of mitochondrial redox signaling","volume":"100","author":"Brand","year":"2016","journal-title":"Free Radical Biology and Medicine"},{"issue":"3","key":"10.1016\/bs.acr.2024.06.004_bib10","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3390\/antiox11030438","article-title":"Redox-related proteins in melanoma progression","volume":"11","author":"Carvalho","year":"2022","journal-title":"Antioxidants"},{"issue":"5","key":"10.1016\/bs.acr.2024.06.004_bib11","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3390\/antiox13050555","article-title":"Modeling Melanoma Heterogeneity In Vitro: Redox, Resistance and Pigmentation Profiles","volume":"13","author":"Carvalho","year":"2024","journal-title":"Antioxidants"},{"issue":"6","key":"10.1016\/bs.acr.2024.06.004_bib12","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/pcmr.12398","article-title":"The role of thioredoxin reductase 1 in melanoma metabolism and metastasis","volume":"28","author":"Cassidy","year":"2015","journal-title":"Pigment Cell & Melanoma Research"},{"issue":"1","key":"10.1016\/bs.acr.2024.06.004_bib13","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12943-017-0667-y","article-title":"ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells","volume":"16","author":"Cesi","year":"2017","journal-title":"Molecular Cancer"},{"issue":"26","key":"10.1016\/bs.acr.2024.06.004_bib14","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/bs.acr.2024.06.004_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2023.102703","article-title":"The ferroptosis inducing compounds RSL3 and ML162 are not direct inhibitors of GPX4 but of TXNRD1","volume":"62","author":"Cheff","year":"2023","journal-title":"Redox Biology"},{"key":"10.1016\/bs.acr.2024.06.004_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2022.102294","article-title":"Redox proteome analysis of auranofin exposed ovarian cancer cells (A2780)","volume":"52","author":"Chiappetta","year":"2022","journal-title":"Redox Biology"},{"issue":"2","key":"10.1016\/bs.acr.2024.06.004_bib17","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/exd.12613","article-title":"Mitochondrial oxidative stress as a novel therapeutic target to overcome intrinsic drug resistance in melanoma cell subpopulations","volume":"24","author":"Cierlitza","year":"2015","journal-title":"Experimental Dermatology"},{"issue":"26","key":"10.1016\/bs.acr.2024.06.004_bib18","doi-asserted-by":"crossref","first-page":"39473","DOI":"10.18632\/oncotarget.7790","article-title":"Mitochondrial oxidative phosphorylation controls cancer cell\u2019s life and death decisions upon exposure to MAPK inhibitors","volume":"7","author":"Corazao-Rozas","year":"2016","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/bs.acr.2024.06.004_bib19","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.18632\/oncotarget.1420","article-title":"Mitochondrial oxidative stress is the Achille\u2019s heel of melanoma cells resistant to Braf-mutant inhibitor","volume":"4","author":"Corazao-Rozas","year":"2013","journal-title":"Oncotarget"},{"issue":"149","key":"10.1016\/bs.acr.2024.06.004_bib20","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2001148","article-title":"BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation","volume":"3","author":"Corcoran","year":"2010","journal-title":"Science Signaling"},{"issue":"4","key":"10.1016\/bs.acr.2024.06.004_bib21","doi-asserted-by":"crossref","first-page":"336","DOI":"10.18632\/oncotarget.262","article-title":"Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers","volume":"2","author":"Corcoran","year":"2011","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/bs.acr.2024.06.004_bib22","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.bcp.2008.08.021","article-title":"The thioredoxin reductase inhibitor auranofin triggers apoptosis through a Bax\/Bak-dependent process that involves peroxiredoxin 3 oxidation","volume":"76","author":"Cox","year":"2008","journal-title":"Biochemical Pharmacology"},{"issue":"1","key":"10.1016\/bs.acr.2024.06.004_bib23","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3390\/cancers3010126","article-title":"Decoding melanoma metastasis","volume":"3","author":"Damsky","year":"2010","journal-title":"Cancers"},{"issue":"7436","key":"10.1016\/bs.acr.2024.06.004_bib24","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nature11814","article-title":"Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance","volume":"494","author":"Das Thakur","year":"2013","journal-title":"Nature"},{"issue":"6892","key":"10.1016\/bs.acr.2024.06.004_bib25","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"issue":"6","key":"10.1016\/bs.acr.2024.06.004_bib26","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1038\/jid.2014.65","article-title":"Melanocytes as instigators and victims of oxidative stress","volume":"134","author":"Denat","year":"2014","journal-title":"Journal of Investigative Dermatology"},{"issue":"2","key":"10.1016\/bs.acr.2024.06.004_bib27","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1755-148X.2011.00950.x","article-title":"Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition","volume":"25","author":"Deng","year":"2012","journal-title":"Pigment Cell & Melanoma Research"},{"issue":"12","key":"10.1016\/bs.acr.2024.06.004_bib28","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.3390\/ijms20123046","article-title":"Proteomics-Metabolomics Combined Approach Identifies Peroxidasin as a Protector against Metabolic and Oxidative Stress in Prostate Cancer","volume":"20","author":"Dougan","year":"2019","journal-title":"International journal of molecular sciences"},{"issue":"7","key":"10.1016\/bs.acr.2024.06.004_bib29","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1158\/0008-5472.CAN-22-1826","article-title":"ROS induction targets persister cancer cells with low metabolic activity in NRAS-mutated melanoma","volume":"83","author":"Eichhoff","year":"2023","journal-title":"Cancer Research"},{"issue":"5","key":"10.1016\/bs.acr.2024.06.004_bib30","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrc3218","article-title":"From genes to drugs: targeted strategies for melanoma","volume":"12","author":"Flaherty","year":"2012","journal-title":"Nature Reviews Cancer"},{"key":"10.1016\/bs.acr.2024.06.004_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2021.101949","article-title":"Auranofin reveals therapeutic anticancer potential by triggering distinct molecular cell death mechanisms and innate immunity in mutant p53 non-small cell lung cancer","volume":"42","author":"Freire Boullosa","year":"2021","journal-title":"Redox Biology"},{"key":"10.1016\/bs.acr.2024.06.004_bib32","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1146\/annurev-pharmtox-052220-102509","article-title":"Thioredoxin reductase inhibition for cancer therapy","volume":"62","author":"Gencheva","year":"2022","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"3","key":"10.1016\/bs.acr.2024.06.004_bib33","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/j.1751-1097.2008.00309.x","article-title":"Melanosomal damage in normal human melanocytes induced by UVB and metal uptake - a basis for the pro-oxidant state of melanoma","volume":"84","author":"Gidanian","year":"2008","journal-title":"Photochemistry and Photobiology"},{"issue":"2","key":"10.1016\/bs.acr.2024.06.004_bib34","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejcsup.2013.07.011","article-title":"Targeted therapy in melanoma\u2013the role of BRAF, RAS and KIT mutations.","volume":"11","author":"Goldinger","year":"2013","journal-title":"European Journal of Cancer Supplements"},{"issue":"12","key":"10.1016\/bs.acr.2024.06.004_bib35","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nrd4002","article-title":"Modulation of oxidative stress as an anticancer strategy","volume":"12","author":"Gorrini","year":"2013","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"10.1016\/bs.acr.2024.06.004_bib36","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jdermsci.2022.12.007","article-title":"Sestrin2 contributes to BRAF inhibitor resistance via reducing redox vulnerability of melanoma cells","volume":"109","author":"Guo","year":"2023","journal-title":"Journal of Dermatological Science"},{"key":"10.1016\/bs.acr.2024.06.004_bib37","series-title":"Free radicals in biology and medicine","author":"Halliwell","year":"2015"},{"key":"10.1016\/bs.acr.2024.06.004_bib38","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.gene.2018.06.076","article-title":"Peroxidasin is a novel target of the redox-sensitive transcription factor Nrf2","volume":"674","author":"Hanmer","year":"2018","journal-title":"Gene"},{"issue":"3","key":"10.1016\/bs.acr.2024.06.004_bib39","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ccr.2013.02.003","article-title":"Oncogenic BRAF regulates oxidative metabolism via PGC1\u03b1 and MITF.","volume":"23","author":"Haq","year":"2013","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/bs.acr.2024.06.004_bib40","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/his.12659","article-title":"Dysregulation of redox-state-regulating enzymes in melanocytic skin tumours and the surrounding microenvironment","volume":"67","author":"Hintsala","year":"2015","journal-title":"Histopathology"},{"issue":"2","key":"10.1016\/bs.acr.2024.06.004_bib41","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","article-title":"A landscape of driver mutations in melanoma","volume":"150","author":"Hodis","year":"2012","journal-title":"Cell"},{"issue":"6","key":"10.1016\/bs.acr.2024.06.004_bib42","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1042\/BST0331375","article-title":"Thiol redox control via thioredoxin and glutaredoxin systems","volume":"33","author":"Holmgren","year":"2005","journal-title":"Biochemical Society Transactions"},{"issue":"1","key":"10.1016\/bs.acr.2024.06.004_bib43","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.bbrc.2010.03.083","article-title":"Thioredoxin and thioredoxin reductase: current research with special reference to human disease","volume":"396","author":"Holmgren","year":"2010","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"27","key":"10.1016\/bs.acr.2024.06.004_bib44","doi-asserted-by":"crossref","first-page":"41186","DOI":"10.18632\/oncotarget.9227","article-title":"Identifying and targeting determinants of melanoma cellular invasion","volume":"7","author":"Jayachandran","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/bs.acr.2024.06.004_bib45","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/908797","article-title":"Role of melanin in melanocyte dysregulation of reactive oxygen species","volume":"2013","author":"Jenkins","year":"2013","journal-title":"BioMed Research International"},{"issue":"3","key":"10.1016\/bs.acr.2024.06.004_bib46","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41419-018-0340-4","article-title":"Glucose metabolism and NRF2 coordinate the antioxidant response in melanoma resistant to MAPK inhibitors","volume":"9","author":"Khamari","year":"2018","journal-title":"Cell Death & Disease"},{"issue":"3","key":"10.1016\/bs.acr.2024.06.004_bib47","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jid.2019.09.010","article-title":"Redox activities of melanins investigated by electrochemical reverse engineering: implications for their roles in oxidative stress","volume":"140","author":"Kim","year":"2020","journal-title":"Journal of Investigative Dermatology"},{"issue":"2","key":"10.1016\/bs.acr.2024.06.004_bib48","doi-asserted-by":"crossref","DOI":"10.1097\/CCO.0000000000000426","article-title":"Development of encorafenib for BRAF-mutated advanced melanoma","volume":"30","author":"Koelblinger","year":"2018","journal-title":"Current Opinion in Oncology"},{"issue":"2","key":"10.1016\/bs.acr.2024.06.004_bib49","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/0003-9861(92)90032-R","article-title":"Generation of superoxide during the enzymatic action of tyrosinase","volume":"292","author":"Koga","year":"1992","journal-title":"Archives of Biochemistry and Biophysics"},{"issue":"15","key":"10.1016\/bs.acr.2024.06.004_bib50","doi-asserted-by":"crossref","first-page":"4744","DOI":"10.1158\/0008-5472.CAN-12-4226","article-title":"Peroxiredoxin-2 represses melanoma metastasis by increasing E-cadherin\/\u03b2-catenin complexes in adherens junctions","volume":"73","author":"Lee","year":"2013","journal-title":"Cancer Research"},{"issue":"3","key":"10.1016\/bs.acr.2024.06.004_bib51","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","article-title":"The Warburg Effect: How Does it Benefit Cancer Cells?","volume":"41","author":"Liberti","year":"2016","journal-title":"Trends in Biochemical Sciences"},{"key":"10.1016\/bs.acr.2024.06.004_bib52","series-title":"Metabolism in Cancer","first-page":"39","article-title":"Metabolic reprogramming by the PI3K-Akt-mTOR pathway in cancer","author":"Lien","year":"2016"},{"issue":"11","key":"10.1016\/bs.acr.2024.06.004_bib53","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.bbagen.2008.06.003","article-title":"Glutaredoxin systems","volume":"1780","author":"Lillig","year":"2008","journal-title":"Biochimica et Biophysica Acta (BBA) - General Subjects"},{"issue":"1","key":"10.1016\/bs.acr.2024.06.004_bib54","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jaad.2014.09.028","article-title":"Outcome of patients with de novo versus nevus-associated melanoma","volume":"72","author":"Lin","year":"2015","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3B","key":"10.1016\/bs.acr.2024.06.004_bib55","first-page":"2425","article-title":"The thioredoxin-thioredoxin reductase system: over-expression in human cancer","volume":"23","author":"Lincoln","year":"2003","journal-title":"Anticancer research"},{"issue":"4","key":"10.1016\/bs.acr.2024.06.004_bib56","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1021\/pr800578a","article-title":"Quantitative differential proteome analysis in an animal model for human melanoma","volume":"8","author":"Lokaj","year":"2009","journal-title":"Journal of Proteome Research"},{"issue":"7","key":"10.1016\/bs.acr.2024.06.004_bib57","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2017.74.1025","article-title":"Long-term outcomes in patients with BRAF V600\u2013mutant metastatic melanoma who received dabrafenib combined with trametinib","volume":"36","author":"Long","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/bs.acr.2024.06.004_bib58","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.freeradbiomed.2013.07.036","article-title":"The thioredoxin antioxidant system","volume":"66","author":"Lu","year":"2014","journal-title":"Free Radical Biology and Medicine"},{"key":"10.1016\/bs.acr.2024.06.004_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2019.108076","article-title":"Hydrogen peroxide-producing NADPH oxidases and the promotion of migratory phenotypes in cancer","volume":"675","author":"Meitzler","year":"2019","journal-title":"Archives of Biochemistry and Biophysics"},{"key":"10.1016\/bs.acr.2024.06.004_bib60","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.redox.2017.05.016","article-title":"Decoding NADPH oxidase 4 expression in human tumors","volume":"13","author":"Meitzler","year":"2017","journal-title":"Redox Biology"},{"issue":"17","key":"10.1016\/bs.acr.2024.06.004_bib61","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1089\/ars.2013.5603","article-title":"NADPH oxidases: a perspective on reactive oxygen species production in tumor biology","volume":"20","author":"Meitzler","year":"2014","journal-title":"Antioxid Redox Signal"},{"issue":"1","key":"10.1016\/bs.acr.2024.06.004_bib62","doi-asserted-by":"crossref","first-page":"7847","DOI":"10.1038\/s41598-021-86329-5","article-title":"Low expression of the PPAR\u03b3-regulated gene thioredoxin-interacting protein accompanies human melanoma progression and promotes experimental lung metastases","volume":"11","author":"Meylan","year":"2021","journal-title":"Scientific Reports"},{"issue":"12","key":"10.1016\/bs.acr.2024.06.004_bib63","doi-asserted-by":"crossref","first-page":"4853","DOI":"10.1158\/0008-5472.CAN-07-6787","article-title":"Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma","volume":"68","author":"Montagut","year":"2008","journal-title":"Cancer Research"},{"issue":"1","key":"10.1016\/bs.acr.2024.06.004_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BJ20081386","article-title":"How mitochondria produce reactive oxygen species","volume":"417","author":"Murphy","year":"2009","journal-title":"Biochemical Journal"},{"issue":"10","key":"10.1016\/bs.acr.2024.06.004_bib65","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1016\/j.freeradbiomed.2012.03.017","article-title":"The oncology drug elesclomol selectively transports copper to the mitochondria to induce oxidative stress in cancer cells","volume":"52","author":"Nagai","year":"2012","journal-title":"Free Radical Biology and Medicine"},{"issue":"7326","key":"10.1016\/bs.acr.2024.06.004_bib66","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature09626","article-title":"Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation","volume":"468","author":"Nazarian","year":"2010","journal-title":"Nature"},{"issue":"1","key":"10.1016\/bs.acr.2024.06.004_bib67","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/1479-5876-9-76","article-title":"Combination therapy with vemurafenib (PLX4032\/RG7204) and metformin in melanoma cell lines with distinct driver mutations","volume":"9","author":"Niehr","year":"2011","journal-title":"Journal of Translational Medicine"},{"issue":"4","key":"10.1016\/bs.acr.2024.06.004_bib68","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1158\/2159-8290.CD-13-0440","article-title":"Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis","volume":"4","author":"Parmenter","year":"2014","journal-title":"Cancer Discovery"},{"key":"10.1016\/bs.acr.2024.06.004_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2021.102090","article-title":"Peroxidasin protein expression and enzymatic activity in metastatic melanoma cell lines are associated with invasive potential","author":"Paumann-Page","year":"2021","journal-title":"Redox Biology"},{"key":"10.1016\/bs.acr.2024.06.004_bib70","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/nature15726","article-title":"Oxidative stress inhibits distant metastasis by human melanoma cells","volume":"527","author":"Piskounova","year":"2015","journal-title":"Nature"},{"issue":"1","key":"10.1016\/bs.acr.2024.06.004_bib71","doi-asserted-by":"crossref","first-page":"53","DOI":"10.14348\/molcells.2016.2330","article-title":"Distribution and features of the six classes of peroxiredoxins","volume":"39","author":"Poole","year":"2016","journal-title":"Molecules and cells"},{"issue":"2","key":"10.1016\/bs.acr.2024.06.004_bib72","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.bbagen.2013.08.001","article-title":"Peroxiredoxins as biomarkers of oxidative stress","volume":"1840","author":"Poynton","year":"2014","journal-title":"Biochimica et Biophysica Acta (BBA) - General Subjects"},{"issue":"1","key":"10.1016\/bs.acr.2024.06.004_bib73","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.redox.2013.04.005","article-title":"Sites of reactive oxygen species generation by mitochondria oxidizing different substrates","volume":"1","author":"Quinlan","year":"2013","journal-title":"Redox Biology"},{"issue":"7","key":"10.1016\/bs.acr.2024.06.004_bib74","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1136\/jclinpath-2019-206173","article-title":"PRDX3 is associated with metastasis and poor survival in uveal melanoma","volume":"73","author":"Ramasamy","year":"2020","journal-title":"Journal of Clinical Pathology"},{"key":"10.1016\/bs.acr.2024.06.004_bib76","doi-asserted-by":"crossref","DOI":"10.1021\/ml4000063","article-title":"Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors","author":"Rheault","year":"2013","journal-title":"ACS Medicinal Chemistry Letters, 4(3), 358-362"},{"issue":"1","key":"10.1016\/bs.acr.2024.06.004_bib77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14348\/molcells.2016.2368","article-title":"Overview on peroxiredoxin","volume":"39","author":"Rhee","year":"2016","journal-title":"Molecules and cells"},{"issue":"7","key":"10.1016\/bs.acr.2024.06.004_bib78","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1080\/10715760500135391","article-title":"Effect of auranofin on the mitochondrial generation of hydrogen peroxide - role of thioredoxin reductase","volume":"39","author":"Rigobello","year":"2005","journal-title":"Free Radical Research"},{"issue":"30","key":"10.1016\/bs.acr.2024.06.004_bib79","doi-asserted-by":"crossref","first-page":"48081","DOI":"10.18632\/oncotarget.10129","article-title":"NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells","volume":"7","author":"Rocha","year":"2016","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/bs.acr.2024.06.004_bib80","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1042\/CS20140542","article-title":"NADPH oxidases and cancer","volume":"128","author":"Roy","year":"2015","journal-title":"Clinical Science"},{"issue":"21","key":"10.1016\/bs.acr.2024.06.004_bib81","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1182\/blood.V122.21.3819.3819","article-title":"Auranofin Induces a Reversible In-Vivo Stress Response That Correlates With a Transient Clinical Effect In Patients With Chronic Lymphocytic Leukemia","volume":"122","author":"Saba","year":"2013","journal-title":"Blood"},{"key":"10.1016\/bs.acr.2024.06.004_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2021.102184","article-title":"Comprehensive chemical proteomics analyses reveal that the new TRi-1 and TRi-2 compounds are more specific thioredoxin reductase 1 inhibitors than auranofin","volume":"48","author":"Sabatier","year":"2021","journal-title":"Redox Biology"},{"key":"10.1016\/bs.acr.2024.06.004_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101491","article-title":"Comprehensive chemical proteomics for target deconvolution of the redox active drug auranofin","volume":"32","author":"Saei","year":"2020","journal-title":"Redox Biology"},{"issue":"5","key":"10.1016\/bs.acr.2024.06.004_bib84","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.ajpath.2020.01.012","article-title":"Oxidative phosphorylation promotes primary melanoma invasion","volume":"190","author":"Salhi","year":"2020","journal-title":"The American Journal of Pathology"},{"issue":"1","key":"10.1016\/bs.acr.2024.06.004_bib85","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/phpp.12329","article-title":"Mechanisms and prevention of UV\u2010induced melanoma.","volume":"34","author":"Sample","year":"2018","journal-title":"Photodermatology, photoimmunology & photomedicine"},{"key":"10.1016\/bs.acr.2024.06.004_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114073","article-title":"COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E\/K-mutant melanoma","volume":"204","author":"Schadendorf","year":"2024","journal-title":"European Journal of Cancer"},{"issue":"7260","key":"10.1016\/bs.acr.2024.06.004_bib87","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nature08268","article-title":"Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment","volume":"461","author":"Schafer","year":"2009","journal-title":"Nature"},{"issue":"2","key":"10.1016\/bs.acr.2024.06.004_bib88","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1042\/BJ20141204","article-title":"Peroxiredoxin 6 triggers melanoma cell growth by increasing arachidonic acid-dependent lipid signalling","volume":"471","author":"Schmitt","year":"2015","journal-title":"Biochemical Journal"},{"issue":"49","key":"10.1016\/bs.acr.2024.06.004_bib89","doi-asserted-by":"crossref","first-page":"42626","DOI":"10.1074\/jbc.M111.282046","article-title":"Comparative metabolic flux profiling of melanoma cell lines: beyond the Warburg effect","volume":"286","author":"Scott","year":"2011","journal-title":"Journal of Biological Chemistry"},{"issue":"6","key":"10.1016\/bs.acr.2024.06.004_bib90","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.3390\/cancers12061500","article-title":"Inhibition of Patched Drug Efflux Increases Vemurafenib Effectiveness against Resistant BrafV600E Melanoma","volume":"12","author":"Signetti","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/bs.acr.2024.06.004_bib91","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.gene.2018.01.011","article-title":"Peroxidasin is regulated by the epithelial-mesenchymal transition master transcription factor Snai1","volume":"646","author":"Sitole","year":"2018","journal-title":"Gene"},{"key":"10.1016\/bs.acr.2024.06.004_bib92","article-title":"Peroxidasin is associated with a mesenchymal-like transcriptional phenotype and promotes invasion in metastatic melanoma","volume":"2024","author":"Smith-D\u00edaz","year":"2024","journal-title":"bioRxiv"},{"issue":"S2","key":"10.1016\/bs.acr.2024.06.004_bib93","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ans.17051","article-title":"Contemporary management of locoregionally advanced melanoma in Australia and New Zealand and the role of adjuvant systemic therapy","volume":"91","author":"Smithers","year":"2021","journal-title":"ANZ Journal of Surgery"},{"issue":"428","key":"10.1016\/bs.acr.2024.06.004_bib94","doi-asserted-by":"crossref","first-page":"eaaf7444","DOI":"10.1126\/scitranslmed.aaf7444","article-title":"Irreversible inhibition of cytosolic thioredoxin reductase 1 as a mechanistic basis for anticancer therapy","volume":"10","author":"Stafford","year":"2018","journal-title":"Science translational medicine"},{"key":"10.1016\/bs.acr.2024.06.004_bib95","article-title":"MCU controls melanoma progression through a redox-controlled phenotype switch","volume":"23","author":"Stejerean-Todoran","year":"2022"},{"issue":"4","key":"10.1016\/bs.acr.2024.06.004_bib96","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1158\/0008-5472.CAN-11-1875","article-title":"Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation","volume":"72","author":"Su","year":"2012","journal-title":"Cancer Research"},{"issue":"3","key":"10.1016\/bs.acr.2024.06.004_bib97","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.freeradbiomed.2011.11.019","article-title":"Investigating the role of melanin in UVA\/UVB-and hydrogen peroxide-induced cellular and mitochondrial ROS production and mitochondrial DNA damage in human melanoma cells","volume":"52","author":"Swalwell","year":"2012","journal-title":"Free Radical Biology and Medicine"},{"issue":"11","key":"10.1016\/bs.acr.2024.06.004_bib98","doi-asserted-by":"crossref","first-page":"5753","DOI":"10.1021\/cr4006236","article-title":"Targeting the Achilles Heel of Multidrug-Resistant Cancer by Exploiting the Fitness Cost of Resistance","volume":"114","author":"Szak\u00e1cs","year":"2014","journal-title":"Chemical Reviews"},{"issue":"6282","key":"10.1016\/bs.acr.2024.06.004_bib99","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1126\/science.aad0501","article-title":"Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq","volume":"352","author":"Tirosh","year":"2016","journal-title":"Science"},{"issue":"1","key":"10.1016\/bs.acr.2024.06.004_bib100","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/pcmr.12908","article-title":"Genomic and signalling pathway characterization of the NZM panel of melanoma cell lines: A valuable model for studying the impact of genetic diversity in melanoma","volume":"34","author":"Tran","year":"2021","journal-title":"Pigment Cell & Melanoma Research"},{"issue":"1","key":"10.1016\/bs.acr.2024.06.004_bib101","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12885-021-07826-4","article-title":"Diverse mechanisms activate the PI 3-kinase\/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK","volume":"21","author":"Tran","year":"2021","journal-title":"BMC Cancer"},{"issue":"8","key":"10.1016\/bs.acr.2024.06.004_bib102","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1073\/pnas.0711741105","article-title":"Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity","volume":"105","author":"Tsai","year":"2008","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"7823","key":"10.1016\/bs.acr.2024.06.004_bib103","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41586-020-2623-z","article-title":"Lymph protects metastasizing melanoma cells from ferroptosis","volume":"585","author":"Ubellacker","year":"2020","journal-title":"Nature"},{"issue":"6","key":"10.1016\/bs.acr.2024.06.004_bib104","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.semcancer.2006.09.004","article-title":"On the potential of thioredoxin reductase inhibitors for cancer therapy","volume":"16","author":"Urig","year":"2006","journal-title":"Seminars in Cancer Biology"},{"issue":"5930","key":"10.1016\/bs.acr.2024.06.004_bib105","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg effect: the metabolic requirements of cell proliferation","volume":"324","author":"Vander Heiden","year":"2009","journal-title":"Science"},{"issue":"3","key":"10.1016\/bs.acr.2024.06.004_bib106","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ccr.2012.11.020","article-title":"PGC1\u03b1 expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress","volume":"23","author":"Vazquez","year":"2013","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/bs.acr.2024.06.004_bib107","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/exd.12763","article-title":"Feeling energetic? New strategies to prevent metabolic reprogramming in melanoma","volume":"24","author":"Verduzco","year":"2015","journal-title":"Exp Dermatol"},{"issue":"6","key":"10.1016\/bs.acr.2024.06.004_bib108","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ccr.2010.11.023","article-title":"Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R\/PI3K","volume":"18","author":"Villanueva","year":"2010","journal-title":"Cancer Cell"},{"issue":"37","key":"10.1016\/bs.acr.2024.06.004_bib109","doi-asserted-by":"crossref","first-page":"5590","DOI":"10.1038\/s41388-021-01911-5","article-title":"Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma","volume":"40","author":"Wang","year":"2021","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/bs.acr.2024.06.004_bib110","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.cell.2018.04.012","article-title":"An acquired vulnerability of drug-resistant melanoma with therapeutic potential","volume":"173","author":"Wang","year":"2018","journal-title":"Cell"},{"issue":"9","key":"10.1016\/bs.acr.2024.06.004_bib111","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1027471","article-title":"Thioredoxin induces Tregs to generate an immunotolerant tumor microenvironment in metastatic melanoma","volume":"4","author":"Wang","year":"2015","journal-title":"OncoImmunology"},{"issue":"6","key":"10.1016\/bs.acr.2024.06.004_bib112","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.ccell.2014.10.001","article-title":"Is reliance on mitochondrial respiration a \u201cchink in the armor\u201d of therapy-resistant cancer?","volume":"26","author":"Wolf","year":"2014","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/bs.acr.2024.06.004_bib113","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.apsb.2013.12.001","article-title":"The pharmacological impact of ATP-binding cassette drug transporters on vemurafenib-based therapy","volume":"4","author":"Wu","year":"2014","journal-title":"Acta Pharmaceutica Sinica B"},{"issue":"3","key":"10.1016\/bs.acr.2024.06.004_bib114","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1152\/physrev.00023.2017","article-title":"The KEAP1-NRF2 system: a thiol-based sensor-effector apparatus for maintaining redox homeostasis","volume":"98","author":"Yamamoto","year":"2018","journal-title":"Physiological Reviews"},{"issue":"1","key":"10.1016\/bs.acr.2024.06.004_bib115","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1038\/s41467-021-21549-x","article-title":"Melanoma subpopulations that rapidly escape MAPK pathway inhibition incur DNA damage and rely on stress signalling","volume":"12","author":"Yang","year":"2021","journal-title":"Nature Communications"},{"issue":"11","key":"10.1016\/bs.acr.2024.06.004_bib116","doi-asserted-by":"crossref","first-page":"19124","DOI":"10.1002\/jcb.29240","article-title":"Glutathione peroxidase 3 (GPX3) suppresses the growth of melanoma cells through reactive oxygen species (ROS)\u2010dependent stabilization of hypoxia\u2010inducible factor 1\u2010\u03b1 and 2\u2010\u03b1","volume":"120","author":"Yi","year":"2019","journal-title":"Journal of cellular biochemistry"},{"issue":"45","key":"10.1016\/bs.acr.2024.06.004_bib117","doi-asserted-by":"crossref","first-page":"18226","DOI":"10.1073\/pnas.1317577110","article-title":"Phenformin enhances the therapeutic benefit of BRAF V600E inhibition in melanoma","volume":"110","author":"Yuan","year":"2013","journal-title":"Proceedings of the National Academy of Sciences"}],"container-title":["Advances in Cancer Research","Redox Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065230X24000228?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065230X24000228?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T22:53:46Z","timestamp":1722034426000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065230X24000228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9780443294440"],"references-count":116,"URL":"https:\/\/doi.org\/10.1016\/bs.acr.2024.06.004","relation":{},"ISSN":["0065-230X"],"issn-type":[{"value":"0065-230X","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]}}}